The UK government’s proposals to introduce value-based pricing (VBP) — which aims to create a stronger link between the price the National Health Service pays for a medicine and the value it delivers (and in the process, ostensibly, further incentivize therapeutic innovation) — could actually serve to ‘hinder’ innovation, according to a UK think tank.
PharmExec Blog
Follow Us
RSS
Bookstore
Value-Based Pricing Could Counter Innovation, Says UK Think Tank